Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

Cheap OEM Software
 

Search in our Online Store

Wockhardt to market painkiller in the US, Sixteenth US FDA-approved product Print E-mail
21 Mar 2007
Pharmaceutical and biotechnology major Wockhardt Limited today announced US FDA approval to market painkiller tablets containing a combination of Dextropropoxyphene napsylate and Acetaminophen (DPN + APAP) in the US market.

MUMBAI, India | Mar 20, 2007 |
Pharmaceutical and biotechnology major Wockhardt Limited today announced US FDA approval to market painkiller tablets containing a combination of Dextropropoxyphene napsylate and Acetaminophen (DPN + APAP) in the US market.
“Wockhardt is the world’s largest manufacturer of Dextropropoxyphene and our products based on this drug are sold all over the world,” said Wockhardt chairman Habil Khorakiwala. “This is our sixteenth ANDA approval and our first painkiller to be sold in the US.” Dextropropoxyphene combinations are one of the more potent analgesic drugs and is widely used all over the world for control of various kinds of pain. The US market for the Dextropropoxyphene combination is over $ 100 million and is sold under the brand name Darvocet-N. Wockhardt USA Inc., the company’s wholly-owned subdidiary, will be marketing the painkiller in the US. The DPN + APAP tablets are manufactured at the US FDA-certified formulation plant at Aurangabad, Maharashtra and the active ingredient is manufactured at the US FDA-approved bulk drug plant at Ankleshwar, Gujarat.Wockhardt currently markets 15 products in the US, 10 of which were launched during 2006.Wockhardt is among the few companies with end-to-end integrated capabilities for its products, starting with manufacture of oral and sterile active ingredients, the dosage forms and marketing through its wholly-owned subsidiary in the US, thus enabling the company to capture maximum value.Wockhardt Limited is an internationally approved pharmaceutical and biotechnology company having a strong and innovative research and development programme. Wockhardt has made four successful acquisitions in Europe, where it employs 800 people. It has a wholly-owned subsidiary in USA. Europe and USA together accounts for over half of Wockhardt’s sales.

SOURCE: Wockhardt




Digg!Reddit!Del.icio.us!Google!Live!Facebook!Slashdot!Netscape!Technorati!StumbleUpon!Spurl!Wists!Simpy!Newsvine!Blinklist!Furl!Fark!Blogmarks!Yahoo!Smarking!Netvouz!Shadows!RawSugar!Ma.gnolia!PlugIM!Squidoo!BlogMemes!FeedMeLinks!BlinkBits!Tailrank!linkaGoGo!Free social bookmarking plugins and extensions for Joomla! websites! title=
 

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Diabetes Drug Pipeline

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonists & Antagonists

Order Now

Subscribe La Merie Biologics